34,651 Shares in ChemoCentryx, Inc. (NASDAQ:CCXI) Purchased by Walleye Capital LLC

Walleye Capital LLC purchased a new stake in ChemoCentryx, Inc. (NASDAQ:CCXIGet Rating) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 34,651 shares of the biopharmaceutical company’s stock, valued at approximately $869,000.

Several other large investors have also recently added to or reduced their stakes in CCXI. Prospera Financial Services Inc bought a new stake in ChemoCentryx during the 1st quarter worth approximately $46,000. Point72 Hong Kong Ltd acquired a new stake in shares of ChemoCentryx in the fourth quarter valued at $115,000. Commerce Bank bought a new position in shares of ChemoCentryx in the fourth quarter valued at about $219,000. Envestnet Asset Management Inc. acquired a new position in ChemoCentryx during the 4th quarter worth about $238,000. Finally, HighTower Advisors LLC bought a new stake in ChemoCentryx during the 4th quarter worth about $266,000. 81.09% of the stock is owned by institutional investors.

ChemoCentryx Stock Performance

Shares of NASDAQ:CCXI opened at $51.56 on Tuesday. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of -27.28 and a beta of 1.25. The firm’s 50 day simple moving average is $41.61 and its 200 day simple moving average is $29.46. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.54 and a quick ratio of 4.47. ChemoCentryx, Inc. has a fifty-two week low of $14.95 and a fifty-two week high of $51.78.

Insider Buying and Selling at ChemoCentryx

In other news, CEO Thomas J. Schall sold 130,000 shares of the business’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total value of $6,531,200.00. Following the completion of the transaction, the chief executive officer now owns 2,393,352 shares of the company’s stock, valued at approximately $120,242,004.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Thomas J. Schall sold 130,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company’s stock, valued at approximately $120,242,004.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Susan M. Kanaya sold 46,298 shares of the business’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.17, for a total value of $2,322,770.66. Following the completion of the transaction, the chief financial officer now directly owns 91,317 shares of the company’s stock, valued at $4,581,373.89. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 213,760 shares of company stock valued at $10,749,838. Corporate insiders own 8.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Canaccord Genuity Group lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating and set a $52.00 target price on the stock. in a research report on Friday, August 5th. SVB Leerink lowered ChemoCentryx from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $64.00 to $52.00 in a research report on Friday, August 5th. Stifel Nicolaus downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. StockNews.com upgraded ChemoCentryx from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group began coverage on shares of ChemoCentryx in a research report on Thursday, August 4th. They set a “buy” rating and a $81.00 target price on the stock. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $65.25.

ChemoCentryx Profile

(Get Rating)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Featured Articles

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.